AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01099072 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methylphenidate+carnitine
Description: methylphenidate at a dose of 20-30 mg/day depending on weight (20 mg/day for \<30 Kg and 30 mg/day for >30 Kg)+ Carnitine 500-1500 mg/day (depending on weight )
Study NCT02229344 — intervention group
Intervention type: OTHER
Intervention: No Intervention
Description: Participants with newly diagnosed moderate to severe ulcerative colitis in a tertiary referral hospital within 4 weeks before prior to enrollment will be observed.
Study NCT03754244 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQB3456
Description: Observe the safety and pk when the subjects take TQB3456 p.o. qd
Study NCT01540799 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: ATI Neurostimulation System
Description: ATI Neurostimulator (NS-100) and Remote Controller (RC-200)
Study NCT01540799 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ATI Neurostimulation System
Description: ATI Neurostimulator (NS-100) and Remote Controller (RC-200)
Study NCT03908619 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Omeprazole 20mg
Description: Omeprazole 20mg bd/ Amoxicillin 1g bd/ Clarithromycin 500mg bd for 14 days
Study NCT03908619 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Esomeprazole 20mg
Description: Esomperazole 20mg bd/ Amoxicillin 1g bd/ Clarithromycin 500mg bd for 14 days
Study NCT03908619 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rabeprazole Sodium 20mg
Description: Rabeprazole 20mg bd/ Amoxicillin 1g bd/ Clarithromycin 500mg bd for 14 days
Study NCT03908619 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vonoprazan
Description: Vonoprazan 20mg bd/ Amoxicilllin 1g bd/ Clarithromycin 500mg bd for 7 days
Study NCT01179074 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: oesophageal stenting with self expandable metal stent
Description: oesophageal stent placement for high grade dysphagia in inoperable oesophageal cancer
Study NCT01179074 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Oesophageal stent followed by external beam radiotherapy
Description: 30 Gy in 10 fractions over 2 weeks administered in the stent followed by EBRT group
Study NCT04088344 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: isocaloric diet
Description: a 7-day isocaloric diet
Study NCT04088344 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Hypercaloric diet
Description: A 7-day hypercaloric diet supplemented with carbohydrate-rich food (+ 50% of the subject's energy needs).
Study NCT04088344 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Liquid meal
Study NCT04088344 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Liquid meal
Study NCT04088344 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: PET imaging
Study NCT04088344 — intervention group
Intervention type: RADIATION
Group type: PLACEBO_COMPARATOR
Intervention: PET imaging
Study NCT04088344 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: perfusions of stable tracers
Study NCT04088344 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: perfusions of stable tracers
Study NCT04088344 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Indirect calorimetry
Study NCT04088344 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Indirect calorimetry
Study NCT03405623 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Dynamic needle tip positioning under ultrasound-guidance
Description: The tip of needle is positioned under ultrasound-guidance using dynamic short-axis view.
Study NCT03405623 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional long-axis view
Description: The tip of needle is positioned under ultrasound-guidance using conventional long-axis in-plane view.
Study NCT03639714 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GRT-C901
Description: a patient-specific neoantigen cancer vaccine prime
Study NCT03639714 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GRT-R902
Description: a patient-specific neoantigen cancer vaccine boost
Study NCT03639714 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: nivolumab
Description: anti-PD-1 monoclonal antibody
Study NCT03639714 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ipilimumab
Description: anti-CTLA-4 monoclonal antibody
Study NCT02323698 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Caffeine
Description: Subjects will ingest capsules containing caffeine (up to 6mg/kg). Experiments will begin 30min after consumption to approximately coincide with peak plasma concentrations.Throughout the 30min wait time and experimentation, blood pressure and heart rate will be monitored.
Study NCT02323698 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: AIH
Description: Participants will breathe intermittent low oxygen via air generators. The generators will fill reservoir bags attached to a non-rebreathing face mask. Oxygen concentration will be continuously monitored to ensure delivery of FIO2 (fraction of inspired oxygen) = 0.10±0.02 (hypoxia). Throughout experimentation, blood pressure and heart rate will be monitored.
Study NCT02323698 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: This is a placebo counterpart to the caffeine drug. Subjects will ingest capsules containing dextrose. Experiments will begin 30min after consumption to mimic the caffeine drug protocol. Throughout experimentation, blood oxygenation, blood pressure and heart rate will be monitored.
Study NCT02323698 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: SHAM
Description: This is a placebo counterpart to breathing intermittent low oxygen. Participants will breathe intermittent room air via air generators. The generators will fill reservoir bags attached to a non-rebreathing face mask. Oxygen concentration will be continuously monitored to ensure delivery of FIO2 (fraction of inspired oxygen) = 0.21±0.02 (normoxia). Throughout experimentation, blood pressure and heart rate will be monitored.
Study NCT03678805 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Corticotomy
Description: Perforations in the areas close to the impacted canines will be performed in order to accelerate tooth movement.
Study NCT03678805 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Traditional withdrawal techniques
Description: The impacted canines will be withdrawn using elastic modules.
Study NCT01762280 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Famitinib Malate Capsule
Study NCT01751217 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Functional Family Tx
Study NCT01751217 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Services as Usual
Study NCT02491814 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 1% M.F. Milk
Study NCT02491814 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Yogurt Beverage
Study NCT02491814 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Soy Beverage
Study NCT02491814 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Almond Beverage
Study NCT04274998 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]NOS
Description: Main Study: PET/CT imaging will be used to evaluate neuroinflammation in the brain using the investigational radiotracer \[18F\]NOS.
Study NCT04274998 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [11C]PBR28
Description: Sub-Study: Additional PET/CT imaging will be used to evaluate neuroinflammation in the brain for subjects with specific genetic polymorphism using the investigational radiotracer \[11C\]PBR28 in comparison to \[18F\]NOS.
Study NCT00994344 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darunavir/ritonavir
Description: Darunavir/ritonavir 800/100 mg once daily
Study NCT00994344 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lopinavir/ritonavir
Description: Lopinavir/ritonavir 400/100 mg twice daily
Study NCT02216110 — intervention group
Intervention type: PROCEDURE
Intervention: Surgery
Description: Surgery for early gastric cancer includes distal gastrectomy, total gastrectomy, proximal gastrectomy, and wedge resection
Study NCT04540016 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: [14C]HSK7653
Description: 25 mg of \[14C\]HSK7653 (radioactivity of 80 µCi) capsules are taken under fasted condition.
Study NCT03664596 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Sublimated mare's milk
Description: Supplement obtained through sublimation of mare milk, packed into one-dosage sachet (20g), and dissolved in a warm water (36 degrees of Celcius).
Study NCT03664596 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Sublimated mare's milk
Description: Supplement obtained through sublimation of mare milk, packed into one-dosage sachet (20g), and dissolved in a warm water (36 degrees of Celcius).
Study NCT03664596 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Ursodeoxycholic Acid
Description: Ursodeoxycholic acid in the form of 250 mg capsule.
Study NCT03664596 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ursodeoxycholic Acid
Description: Ursodeoxycholic acid in the form of 250 mg capsule.
Study NCT00545272 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: indacaterol
Description: Indacaterol delivered by multiple dose dry powder inhaler (TWISTHALER® device).
Study NCT00545272 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: formoterol
Description: Formoterol delivered by oral inhalation via AEROLIZER® inhalation device.
Study NCT00545272 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo to indacaterol
Description: Placebo TWISTHALER® device
Study NCT00545272 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo to indacaterol
Description: Placebo TWISTHALER® device
Study NCT00545272 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo to formoterol
Description: Placebo AEROLIZER® device
Study NCT00545272 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo to formoterol
Description: Placebo AEROLIZER® device
Study NCT00545272 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: short acting β2-agonist
Description: 100 μg/ 90 μg salbutamol/albuterol Metered Dose Inhaler (MDI) or equivalent dose of Dry Powder Inhaler (DPI).
Study NCT00545272 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: short acting β2-agonist
Description: 100 μg/ 90 μg salbutamol/albuterol Metered Dose Inhaler (MDI) or equivalent dose of Dry Powder Inhaler (DPI).
Study NCT00545272 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: short acting β2-agonist
Description: 100 μg/ 90 μg salbutamol/albuterol Metered Dose Inhaler (MDI) or equivalent dose of Dry Powder Inhaler (DPI).
Study NCT04491604 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Topical Beremagene Geperpavec
Description: Topical gel of non-integrating, replication-incompetent HSV-1 expressing the human collagen VII protein
Study NCT04491604 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching masked inactive topical gel
Study NCT00586781 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Scandinavian Total Ankle Replacement (STAR)
Description: The device has three parts: two metal bearing surfaces (cobalt-chromium alloy) plates with bars that fit into the bone and one plastic (polyethylene) spacer that moves between the metal plates like a ball bearing. The materials in the S.T.A.R. device are the same materials used in total hip and knee implants.
Study NCT00724867 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Belimumab 1 mg/kg
Description: Belimumab 1 mg/kg IV over one hour every 28 days
Study NCT00724867 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Belimumab 10 mg/kg
Description: Belimumab 10 mg/kg IV over one hour every 28 days
Study NCT02527603 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Boss-Holzach-Matter method
Description: The patient holds both his hands around his knees in a supine position until the dislocated shoulder is reduced
Study NCT02527603 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Spaso method
Description: The physician holds the dislocated arm of the patient in a supine position and proceeds with gentle, soft movements of adduction, flexion and external rotation of the limb in this order until reduction is accomplished.
Study NCT02527603 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-Inflammatory Agents, Non-Steroidal
Description: All patients will be administered a dose of NSAI intra-muscular or orally (Dexketoprofen, Enantyum®) it is part of the normal treatment of these patients to cope with pain.
Study NCT01123551 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nebulized morphine
Description: After randomization, patients will receive 10 mg of morphine (1ml) diluted in 4 ml normal saline and nebulized with 6 l/mn during 10 min. Nebulization will be repeated systematically 3 times every twenty minutes unless the patient pain was resolved (VAPS 30%). In addition, patients receive a bolus of IV placebo(5 ml normal saline . IV placebo (2 ml) will be repeated every 10 minutes if the objective of analgesia was not reached .
Study NCT01123551 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous morphine
Description: After randomization, patients will receive a bolus of 5 mg of IV morphine (5 ml. Then, 2mg of IV morphine (2ml) will be added every 10 minutes if the objective of analgesia was not reached (VAPS >30%). In addition, normal saline (5ml)is nebulized with 6 l/mn during 10 min and will be repeated systematically every 20 minutes unless the patient's pain was not resolved (VAPS >30%).
Study NCT01123551 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous morphine
Description: After randomization, patients will receive a bolus of 5 mg of IV morphine (5 ml. Then, 2mg of IV morphine (2ml) will be added every 10 minutes if the objective of analgesia was not reached (VAPS >30%). In addition, normal saline (5ml)is nebulized with 6 l/mn during 10 min and will be repeated systematically every 20 minutes unless the patient's pain was not resolved (VAPS >30%).
Study NCT04078646 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intervention with soy protein isolate
Description: Test meals will be served to the subjects, containing soy protein isolate:~350 mL carrot/tomato juice (50:50, v/v), with 30 g added soy protein, plus 5 ml peanut oil~as morning test meal, served together with 40 g toasted bread and 20 g of cream-cheese plus 10 g margarine.
Study NCT04078646 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intervention with whey protein
Description: Test meals will be served to the subjects, containing soy protein isolate:~350 mL carrot/tomato juice (50:50, v/v), with 30 g added whey protein isolate, plus 5 ml peanut oil~as morning test meal, served together with 40 g toasted bread and 20 g of cream-cheese plus 10 g margarine.
Study NCT04078646 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intervention without protein addition
Description: Test meals will be served to the subjects, containing soy protein isolate:~350 mL carrot/tomato juice (50:50, v/v), plus 5 ml peanut oil~as morning test meal, served together with 40 g toasted bread and 20 g of cream-cheese plus 10 g margarine.
Study NCT02888678 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Economic Strengthening (Impumelelo)
Description: Economic Strengthening (Impumelelo): This intervention consists of 15 one-hour long sessions on financial education in combination with access to appropriate youth-friendly savings mechanisms.
Study NCT02888678 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HIV Prevention Education (Vhutshilo 2.2)
Description: HIV Prevention Education (Vhutshilo 2.2): This intervention consists of 15 one-hour long sessions that are interactive, skills focused, and cover such topics as expressing one's feelings; dealing with loss and grief; decision-making; coping; gender violence; understanding HIV and other sexually transmitted infections; healthy relationships and staying safe in sexual relationships; and contraception and risks associated with unplanned pregnancy.
Study NCT04407949 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: CPAP Treatment
Description: Comparing events from the CPAP device with the events scored in PSG
Study NCT03975244 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise program
Description: Twelve-week of semi-supervised exercise program. The exercise program will combine resistance and endurance training. Both the volume and intensity of training will start at moderate intensity, and progressively be increased at higher volumes and intensities.
Study NCT01042041 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sorafenib tosylate
Description: Given orally
Study NCT01042041 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin hydrochloride
Description: Given via transarterial/hepatic chemoembolization
Study NCT01042041 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: Given via transarterial/hepatic chemoembolization
Study NCT01042041 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mitomycin C
Description: Given via transarterial/hepatic chemoembolization
Study NCT01042041 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: transarterial chemoembolization
Study NCT01042041 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: hepatic artery embolization
Study NCT05048511 — intervention group
Intervention type: BIOLOGICAL
Intervention: vitamin D estimation
Description: Serum samples to estimate vitamin D status were collected on the sixth day of stimulation
Study NCT02864862 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Immediate implant
Study NCT02864862 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: SCTG
Study NCT02864862 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: ADM
Study NCT03486626 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin to increase pregnancy rate in polycystic ovarian syndrome patients
Study NCT03457064 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: PA+Social Adherence Intervention(PASAI)
Description: While both physical activity programs were tailored to match participants' physical needs and abilities, the PA+Social Adherence Intervention(PASAI) introduced elements to promote and strengthen self-efficacy and social interaction among participants.
Study NCT02706964 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Positron emission tomography/x-ray computed tomography
Description: A whole-body PET/CT will be performed to identify the site and extent of spread.
Study NCT02706964 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Magnetic resonance imaging
Description: A brain MRI will be performed.
Study NCT02706964 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: x-ray computed tomography (CT)
Description: A CT scan will be performed to identify the site and extent of spread.
Study NCT03976804 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: low dose CT scan
Description: Lung cancer screening will be based on the analysis of a low dose CT scan
Study NCT03976804 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: blood sample collection
Description: establish a phenotyping of immunity, blood inflammation and digestive and tumour microbiota
Study NCT03976804 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: faecal sample collection
Description: establish a phenotyping of immunity, blood inflammation and digestive and tumour microbiota
Study NCT00124046 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgery
Description: Surgery for this diagnosis is a standard of care, as is the medical treatment. We are comparing the two
Study NCT00124046 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Medical Treatment
Description: Surgery for this diagnosis is a standard of care, as is the medical treatment. We are comparing the two
Study NCT02491814 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Water
Study NCT04327193 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Titrated PEEP based on driving pressure
Description: Alveolar recruitment and PEEP titration is performed at three time points: after intubation, after Trendelenburg, and after supine after CO2 deflation. The level of PEEP which makes the driving pressure lowest is selected and applied during the operation.
Study NCT04327193 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional PEEP
Description: Alveolar recruitment is performed at three time points: after intubation, after Trendelenburg, and after supine after CO2 deflation. Conventional PEEP (5cmH2O) is applied during the operation.
Study NCT02491814 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Breakfast cereal
Study NCT02213601 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Yoga